KR20210016365A - 새로운 약제학적 용도 - Google Patents

새로운 약제학적 용도 Download PDF

Info

Publication number
KR20210016365A
KR20210016365A KR1020207034257A KR20207034257A KR20210016365A KR 20210016365 A KR20210016365 A KR 20210016365A KR 1020207034257 A KR1020207034257 A KR 1020207034257A KR 20207034257 A KR20207034257 A KR 20207034257A KR 20210016365 A KR20210016365 A KR 20210016365A
Authority
KR
South Korea
Prior art keywords
compound
kit
parts
formulation
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020207034257A
Other languages
English (en)
Korean (ko)
Inventor
밍 구
벵트 잉에마르 사무엘손
잰-크리스터 잰슨
Original Assignee
장인 우선 파마슈티컬 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 장인 우선 파마슈티컬 컴퍼니 리미티드 filed Critical 장인 우선 파마슈티컬 컴퍼니 리미티드
Publication of KR20210016365A publication Critical patent/KR20210016365A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020207034257A 2018-05-28 2019-05-27 새로운 약제학적 용도 Pending KR20210016365A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018088701 2018-05-28
CNPCT/CN2018/088701 2018-05-28
PCT/CN2019/088593 WO2019228307A1 (en) 2018-05-28 2019-05-27 New pharmaceutical use

Publications (1)

Publication Number Publication Date
KR20210016365A true KR20210016365A (ko) 2021-02-15

Family

ID=68697381

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207034257A Pending KR20210016365A (ko) 2018-05-28 2019-05-27 새로운 약제학적 용도

Country Status (8)

Country Link
US (2) US20210196783A1 (https=)
EP (1) EP3802562A4 (https=)
JP (1) JP7742226B2 (https=)
KR (1) KR20210016365A (https=)
CN (1) CN112236440A (https=)
MA (1) MA52794A (https=)
TW (1) TW202016127A (https=)
WO (1) WO2019228307A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020000029A (es) * 2017-07-05 2020-08-06 Jiangyin Mucocare Pharmaceutical Co Ltd Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon.
CN113613657A (zh) * 2019-01-10 2021-11-05 江阴优培尔康药业有限公司 含有白三烯受体拮抗剂的新型配制品
MX2022003057A (es) * 2019-09-14 2022-06-16 Jiangyin Usun Pharmaceutical Co Ltd Nuevos peptidos.
CA3160167A1 (en) * 2019-12-02 2021-06-10 Ming Gu Peptides and their use in the treatment of inflammation
US20230372324A1 (en) * 2020-10-13 2023-11-23 Diomed Developments Ltd. Gel formulations comprising montelukast
WO2022193186A1 (en) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. New diagnostic and therapeutic agents
US20240165247A1 (en) * 2021-03-17 2024-05-23 Jiangyin Usun Pharmaceutical Co., Ltd. New peptide conjugates
EP4665372A1 (en) * 2023-02-13 2025-12-24 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. New multi-functional oligopeptides
WO2024260465A1 (en) 2023-06-22 2024-12-26 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. New multi-functional oligopeptides
WO2025195444A1 (en) 2024-03-20 2025-09-25 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. New use of peptides derived from vasoactive intestinal peptide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039128A1 (en) * 1995-06-06 1996-12-12 Hemosphere, Inc. Protein particles for therapeutic and diagnostic use
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
EP1851237A4 (en) * 2005-02-16 2009-01-07 Univ California PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING BONE DISORDERS
EP2101547B1 (de) 2008-03-11 2014-03-05 Vita Zahnfabrik H. Rauter GmbH & Co. KG Dental-Sinterofen sowie Verfahren zum Sintern keramischer Dental-Elemente
JP2012526155A (ja) 2009-08-25 2012-10-25 ポステック アカデミー−インダストリー ファンデーション イガイ接着蛋白質またはその変異体に陰イオン性高分子が含まれたコアセルベート
WO2013167298A1 (en) * 2012-05-11 2013-11-14 Kael-Gemvax Co., Ltd. Anti-inflammatory peptides and composition comprising the same
CN105392468A (zh) * 2013-05-20 2016-03-09 高敏 贻贝粘蛋白凝胶的制备方法、贻贝粘蛋白凝胶及其应用
KR102468519B1 (ko) * 2015-07-20 2022-11-21 장인 벵트 아이. 사무엘손 인스티튜트 오브 라이프 사이언스 컴퍼니 리미티드 피부 염증의 억제에서의 홍합 접착 단백질 제품 및 이의 적용
WO2017028025A1 (zh) 2015-08-14 2017-02-23 江阴市本特塞缪森生命科学研究院有限公司 贻贝粘蛋白产品及其抑制粘膜炎症的应用
WO2017181372A1 (zh) 2016-04-20 2017-10-26 江阴市本特塞缪森生命科学研究院有限公司 贻贝粘蛋白产品及其抑制血管炎症的应用
CN106581656A (zh) * 2016-12-30 2017-04-26 江阴贝瑞森生化技术有限公司 一种用于小儿舌舔皮炎的软膏
WO2019011286A1 (en) * 2017-07-14 2019-01-17 Jiangyin Usun Pharmaceutical Co., Ltd. ANTIVIRAL USE OF MEMBRANE ADHESIVE PROTEINS

Also Published As

Publication number Publication date
JP2021525242A (ja) 2021-09-24
TW202016127A (zh) 2020-05-01
US20250041377A1 (en) 2025-02-06
CN112236440A (zh) 2021-01-15
WO2019228307A1 (en) 2019-12-05
MA52794A (fr) 2021-04-14
US20210196783A1 (en) 2021-07-01
JP7742226B2 (ja) 2025-09-19
EP3802562A4 (en) 2022-06-01
EP3802562A1 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
US20250302818A1 (en) Topical formulations comprising montelukast and combinations with mussel adhesive proteins
US20250041377A1 (en) Pharmaceutical use
US12129313B2 (en) Anti-inflammatory use of peptide
US20230348536A1 (en) Conjugates of montelukast and peptides
HK40058104A (en) Topical formulations comprising combinations of montelukast and mussel adhesion proteins
HK40082364A (en) Topical formulations comprising combinations of montelukast and mussel adhesion proteins
HK40011773B (zh) 肽的抗炎用途
HK40014584A (en) Topical formulations comprising montelukast and combinations with mussel adhesive proteins
HK40014584B (en) Topical formulations comprising montelukast and combinations with mussel adhesive proteins
HK40011773A (en) Anti-inflammatory use of peptide

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000